Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism.

Martin MinerChristina WangJed KaminetskyMohit KheraIrwin GoldsteinCulley CarsonNachiappan ChidambaramShelby KingAdrian Dobs

Published in: Andrology (2024)

Male patients with hypogonadism receiving oral testosterone undecanoate 225 mg twice daily demonstrated improvements in libido and sexual frequency. Serum testosterone concentrations were within the reference range in 87% of patients without dose titration.

Keyphrases

replacement therapy
end stage renal disease
smoking cessation
ejection fraction
newly diagnosed
chronic kidney disease
physical activity
mental health
prognostic factors
patient reported outcomes
patient reported